Efficacy and Safety of Pevonedistat Plus Azacitidine Vs Azacitidine Alone in Higher-Risk Myelodysplastic Syndromes From Study P-2001

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 01期
关键词：
NEDD8-ACTIVATING ENZYME; INHIBITOR;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：11 / 13
页数：3
相关论文
共 50 条
  • [1] Pevonedistat Plus Azacitidine vs Azacitidine Alone in Higher-Risk Myelodysplastic Syndromes (MDS): Efficacy and Safety Results from Study P-2001 (NCT02610777)
    Watts, Justin
    Sekeres, Mikkael
    Radinoff, Atanas
    Arnan, Montserrat
    Cerrano, Marco
    Lopez, Patricia Font
    Zeidner, Joshua
    Campelo, Maria Diez
    Graux, Carlos
    Liesveld, Jane
    Selleslag, Dominik
    Tzvetkov, Nikolai
    Fram, Robert
    Zhao, Dan
    Friedlander, Sharon
    Galinsky, Kevin
    Faller, Douglas
    Ades, Lionel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S347 - S348
  • [2] Pevonedistat (P) plus azacitidine (A) vs A alone in higher-risk myelodysplastic syndromes (HR-MDS): efficacy and safety results from study P-2001 (NCT02610777)
    Giagounidis, A.
    Sekeres, M. A.
    Watts, J.
    Radinoff, A.
    Arnan, M.
    Cerrano, M.
    Lopez, Font P.
    Zeidner, J. F.
    Campelo, Diez M.
    Graux, C.
    Liesveld, J.
    Selleslag, D.
    Tzvetkov, N.
    Fram, R. J.
    Zhou, D.
    Friedlander, S.
    Galinsky, K.
    Faller, D., V
    Ades, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 30 - 30
  • [3] PEVONEDISTAT (P) PLUS AZACITIDINE (A) VS A ALONE IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS): EFFICACY AND SAFETY RESULTS FROM STUDY P-2001 (NCT02610777)
    Santini, V.
    Sekeres, M. A.
    Watts, J.
    Radinoff, A.
    Arnan, M.
    Cerrano, M.
    Font Lopez, P.
    Zeidner, J. F.
    Diez Campelo, M.
    Graux, C.
    Liesveld, J.
    Selleslag, D.
    Tzvetkov, N.
    Fram, R. J.
    Zhao, D.
    Friedlander, S.
    Galinsky, K.
    Faller, D. V.
    Ades, L.
    HAEMATOLOGICA, 2021, 106 (10) : 2 - 3
  • [4] Effectiveness of azacitidine in higher-risk myelodysplastic syndromes
    Dinmohamed, A. G.
    van Norden, Y.
    van de Loosdrecht, A. A.
    Jongen-Lavrencic, M.
    LEUKEMIA, 2016, 30 (08) : 1795 - +
  • [5] Effectiveness of azacitidine in higher-risk myelodysplastic syndromes
    A G Dinmohamed
    Y van Norden
    A A van de Loosdrecht
    M Jongen-Lavrencic
    Leukemia, 2016, 30 : 1795 - 1796
  • [6] Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
    Ades, Lionel
    Girshova, Larisa
    Doronin, Vadim A.
    Diez-Campelo, Maria
    Valcarcel, David
    Kambhampati, Suman
    Viniou, Nora-Athina
    Woszczyk, Dariusz
    De Paz Arias, Raquel
    Symeonidis, Argiris
    Anagnostopoulos, Achilles
    Ciliao Munhoz, Eduardo
    Platzbecker, Uwe
    Santini, Valeria
    Fram, Robert J.
    Yuan, Ying
    Friedlander, Sharon
    Faller, Douglas, V
    Sekeres, Mikkael A.
    BLOOD ADVANCES, 2022, 6 (17) : 5132 - 5145
  • [7] Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes
    Chou, Wen-Chien
    Yeh, Su-Peng
    Hsiao, Liang-Tsai
    Lin, Sheng-Fung
    Chen, Yeu-Chin
    Chen, Tsai-Yun
    Laille, Eric
    Galettis, Anoula
    Dong, Qian
    Songer, Steve
    Beach, C. L.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (05) : E430 - E439
  • [8] Pevonedistat plus azacitidine versus azacitidine alone in patients with higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia or low-blast acute myelogenous leukemia: a phase 2 randomized study
    Ades, Lionel
    Watts, Justin
    Radinoff, Atanas
    Arnan Sangerman, Montserrat
    Cerrano, Marco
    Font Lopez, Patricia
    Zeidner, Joshua F.
    Diez Campelo, Maria
    Graux, Carlos
    Liesveld, Jane
    Selleslag, Dominik
    Tzvetkov, Nikolay
    Fram, Robert J.
    Zhao, Dan
    Bell, Jill
    Friedlander, Sharon
    Faller, Douglas V.
    Sekeres, Mikkael A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 6 - 7
  • [9] Magrolimab plus Azacitidine Versus Azacitidine plus Placebo in Untreated Higher-Risk (HR) Myelodysplastic Syndromes (MDS): The Phase 3, Randomized, ENHANCE Study
    Garcia-Manero, Guillermo
    Daver, Naval
    Xu, Jin
    Chao, Mark
    Chung, Trisha
    Tan, Anderson
    Wang, Yan
    Wei, Andrew
    Vyas, Paresh
    Sallman, David
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S343 - S344
  • [10] Azacitidine and Venetoclax Combination for Upfront Treatment of Higher-Risk Myelodysplastic Syndromes
    Al Ali, Najla
    Sallman, David
    Chan, Onyee
    Padron, Eric
    Sweet, Kendra
    Kuykendall, Andrew
    Lancet, Jeffrey
    Komrokji, Rami
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S341 - S341
12345